海普瑞(09989.HK)候选药物H1710临床试验获批

阿斯达克财经
18 Feb

海普瑞(09989.HK) 公布,于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,批准公司自主研发的候选药物注射用H1710开展临床试验,适应症为晚期实体瘤。

H1710是一种高效高选择性的乙酰肝素酶抑制剂,海普瑞指,临床前研究已表明H1710通过抑制乙酰肝素酶的活性和表达表现出抗肿瘤药理活性,在多种肿瘤动物模型中均展示出显著的抑瘤作用。截至目前,于全球范围内尚无同一分子机制的同类产品上市。(gc/j)(港股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10